Bupropion, a FDA-approved antidepressant and smoking cessation aid, blocks dopamine and norepinephrine reuptake transporters and non-competitively inhibits nicotinic acetylcholine (nACh) and serotonin type 3A (5-HT 3 ) receptors. 5-HT 3 receptors are pentameric ligand-gated ion channels that regulate synaptic activity in the central and peripheral nervous system pre-and postsynaptically. In the present study, we examined and compared the effect of bupropion and its active metabolite hydroxybupropion on homomeric 5-HT 3A and heteromeric mouse 5-HT 3AB receptors expressed in Xenopus laevis oocytes using two-electrode voltage clamp experiments. Co-application of bupropion or hydroxybupropion with 5-HT dose-dependently inhibited 5-HT-induced currents in 5-HT 3AB Rs (IC 50 = 866 μ M and 505 μ M, respectively) but potentiated 5-HT-induced currents at low (30-50 μ M) concentrations. The corresponding IC 50 s for bupropion and hydroxybupropion with 5-HT 3A R were 10-and 5-fold lower, respectively (87 μ M and 113 μ M), and no potentiation was observed. The inhibition of 5-HT 3A R and 5-HT 3AB R was non-use dependent and voltage-independent, indicating bupropion is not an open channel blocker. The inhibition by bupropion was reversible and time-dependent. Of note, pre-incubation with a low concentration of bupropion that mimics therapeutic drug conditions significantly inhibited 5-HT induced currents in 5-HT 3A and even more so 5-HT 3AB receptors. In summary, our results indicate that bupropion inhibits 5-HT 3AB R, as well as homomeric receptors, and that this inhibition takes place at clinically-relevant concentrations. Inhibition of 5-HT 3 receptors by bupropion may contribute to its desired and/or undesired clinical effects.
Introduction
The 5-hydroxytryptamine-3 (5-HT 3 ) receptor is an ionotropic receptor and a member of the Cys-loop family of pentameric ligand-gated ion channels (pLGICs) and thereby differs from G-protein-coupled serotonin receptors (5-HT 1 to 5-HT 7 ) (Hannon, 2008; Hoyer, 2002; Thompson, 2007) . 5-HT 3 R is similar in structure and function to the other members of the pLGICs, including the cation-selective nicotinic acetylcholine receptor (nAChR) and the anion-selective γ -amino butyric acid (GABA A ) and glycine receptors.
Malfunction in these receptors has been linked to several neurological disorders (Hogg, 2003; Lemoine, 2012) . Together, they are responsible for fast neurotransmission in the central and peripheral nervous system (Thompson, 2013) and are involved in virtually all brain functions (Hassaine, 2014) .
To date, five different 5-HT 3 subunits have been identified (5-HT 3A -5-HT 3E ). The first subunit to be cloned, 5-HT 3A (Maricq, 1991) , is the only subunit that can form functional homo-oligomeric receptors on the cell membrane when expressed in Xenopus oocytes or cell lines (Hussy, 1994) . Introduction of the 5-HT 3B subunit, to form functional heteromers, altered the properties of the homo-oligomer that more closely resembled at a holding potential of -60 mV, unless otherwise stated. The oocytes were held in a 250 µL chamber and perfused with base solutions (OR-2) using gravity flow at an approximate rate of 5mL/min. Drugs and serotonin were dissolved in the same solution and applied by gravity perfusion. All solutions were applied to a single oocyte until currents reached a steady state before switching solutions. The glass microelectrodes were filled with 3 M KCl and had a resistance of below 2 MΩ. Agonists/antagonists were applied until stable response or desensitization was observed to record maximal current response.
Oocyte membrane preparation
Oocytes expressing 5-HT 3A R and 5-HT 3AB R were homogenized and the membranes were isolated as described before (Pandhare, 2017) . The oocytes were homogenized with a 0.5 mL pestle in ice-cold vesicle dialysis buffer (VDB: 100 uL/oocyte: 96 mM NaCl, 0.1 mM EDTA, 10 mM MOPS, 0.02% NaN 3 , pH 7.5), supplemented with protease inhibitor cocktail III [2 uL/mL]) and centrifuged (800 g for 10 min at 4 °C). The supernatant was collected and the membranes containing the receptors were obtained by high-speed centrifugation (39,000g for 1 h at 4 °C). Membranes were resuspended in VDB (3 μ L/ oocyte) containing PI cocktail and stored at -80 °C.
Western Blotting
For SDS-electrophoresis, 3 μ L of the resuspended membrane pellets containing the receptors were run alongside membrane pellet of uninjected oocyte on 4-15% precast gradient TGX Stain-FreeTM gels (Bio-Rad Laboratories) for 34 min at 200 V. Proteins were transferred to PVDF membrane using the Trans-Blot Turbo Transfer System (Bio-Rad). The membranes were blocked with 5% blotting-grade blocker (Bio-Rad) in Trisbuffered Saline with Tween (TTBS) (100 μ M Tris pH 7.5, 0.9% NaCl, 1% Tween-20) [25 -30 mL/membrane]) for one hour up to overnight. The membranes were incubated with the primary V5 HRP-conjugated antibody (1:5,000, V5-HRP antibody, invitrogen) in TTBS (5% blotting-grade blocker) for one hour at RT. After the removal of the primary antibody, the membranes were washed 4x for 5min each with TTBS and one 5-min wash with TBS. Proteins were visualized by chemiluminescent detection (Image Quant) of peroxidase substrate activity (SuperSignal West Femto Maximum Sensitivity Substrate, Thermo Scientific).
Data Analysis
All electrophysiological data was analyzed with pClamp, Origin (OriginLab Corporation;
Northampton, MA) and Prism 6 Software (GraphPad Prism®; La Jolla, CA). Data is represented as the mean ± S.E.M, maximal current induced by 5-HT was used as the normalizing standard (100% current response) for other current responses in the same oocyte. Statistical significance was determined with paired or unpaired t-test (in Origin) with a cutoff for significance of 0.05 (*p ≤ 0.05 **p ≤ 0.01 ***p ≤ 0.001). The 5-HT (agonist stimulation -1a), bupropion, or hydroxybupropion (antagonist inhibition -1b) concentration dependence on 5-HT 3 currents was fitted using the variable-slope sigmoidal dose response curve equations:
Where I max is the current activated at saturating 5-HT concentration, EC 50 is the agonist concentration producing 50% of the maximal Imax, IC 50 is the concentration of antagonist producing 50% inhibition of I max , X is the agonist (1a) or antagonist (1b) concentration, and n H is the Hill coefficient. All figures and graphs were made in Origin and Adobe Illustrator CC 2018.
Results

Differentiating between 5-HT 3A R and 5-HT 3AB R
To evaluate the effect of bupropion and its major metabolite hydroxybupropion (Fig 1) on homomeric and heteromeric 5-HT 3 receptors, we expressed the mouse 5-HT 3A R and 5-HT 3AB R (in a 1:3 A to B ratio (Corradi, 2015; Thompson, 2013) ) in Xenopus oocytes.
First, we substantiated the obvious difference between the two receptor types (Fig 1) .
The application of the agonist serotonin (5-HT) to Xenopus oocytes expressing 5-HT 3A R ( Fig 1A, top trace) or 5-HT 3AB R (Fig 1A, bottom trace) elicits a rapid inward current with a concentration-dependent amplitude. The currents resulting from a range of 5-HTconcentrations were used to calculate the concentrations that produce a half-maximal response ( Fig 1B) , yielding EC 50 values of 0.80 μ M (n= 5, Hill slope [n H ] of 2.53±0.26)
for 5-HT 3A R and 4.30 μ M (n = 8; n H = 1.04±0.02) for 5-HT 3AB R (Table 1) . Our EC 50 value for mouse 5-HT 3A R and 5-HT 3AB R are comparable to other values reported previously (Hanna, 2000; Hayrapetyan, 2005; Jansen, 2008; Lochner, 2010; Thompson, 2008) . In rodents, the difference between EC 50 values for 5-HT 3A and 5-HT 3AB receptors are smaller as compared to the human subunits, nonetheless, the heteromeric receptor shows fast characteristic desensitization kinetics ( Fig 1C) and a right-shift in potency ( Fig 1B) .
Effect of Bupropion on 5-HT 3A R and 5-HT 3AB R 5-HT and a wide range of bupropion concentrations (A: 10 -1000 µM; AB: 30 -4000 µM) were co-applied to Xenopus oocytes expressing homomeric 5-HT 3A R (Fig 2A, top) or heteromeric 5-HT 3AB R (Fig 2A, bottom) under two-electrode voltage clamp. 5-HT was applied at a concentration that elicits approximately 30% of the maximal response (EC 30 , 5-HT 3A R: 0.5 µM, 5-HT 3AB R: 2 µM). Both traces in Fig. 2A show representative current responses at -60 mV. The first inward current represents the control current evoked by 5-HT alone, followed by subsequent currents obtained by the co-application of 5-HT (EC 30 ) and increasing concentrations of bupropion, which dose-dependently inhibited 5-HT-induced currents for 5-HT 3A and 5-HT 3AB receptors. The concentrations inhibiting 50% of the control currents (IC 50 ) were 87.1 µM (n H =1.28±0.07, n=5) and 866 µM (n H =2.07±0.20, n=7) for A and AB respectively ( Fig. 2B ; Table 1 ). Bupropion's potency at 5-HT 3AB R was 10-fold lower when compared to 5-HT 3A R (unpaired t, t(10)=9.49, p=0.0000784). Notably, small potentiation of 5-HT-evoked currents was observed at low concentrations of bupropion ( Fig. 2A bottom bar graph, 30 µM bupropion led to a 22.6% increase in current), and was therefore excluded from the IC 50 fitting and analysis. Bupropion alone did not elicit an inward current for either receptor ( Fig 2C) .
Effect of Hydroxybupropion on 5-HT 3A R and 5-HT 3AB R
Hydroxybupropion, a major metabolite of bupropion, is involved in bupropion's therapeutic effect, as it also inhibits DA/NE transporters, nAChRs, and 5-HT 3A R (Bondarev, 2003; Damaj, 2004; Pandhare, 2017) . Similar to bupropion, hydroxybupropion inhibited 5-HT 3A R and 5-HT 3AB R dose-dependently when co-applied with 5-HT ( Fig 3A) . The hydroxybupropion concentrations reducing the 5-HT-evoked currents to 50% of the initial response were 113 µM (n=5, n H =1.17±0.06) for 5-HT 3A R and 505 µM (n=8, n H =1.57±0.12) for 5-HT 3AB R ( Fig. 3B ; Table 1 ). Similar to bupropion, the potency of hydroxybupropion for 5-HT 3AB R was right-shifted, resulting in a higher IC 50 value when compared to 5-HT 3A R, although to a lesser extent than bupropion (unpaired t, t(9)=16.26, p=0.000000185). Interestingly, low (50 μ M) hydroxybupropion concentrations also led to small potentiation of 5-HT 3AB R currents, which therefore were excluded from IC 50 fitting and evaluations ( Fig. 3A bar graph, average of 9.94% increase from initial current with 50 μ M hydroxybupropion). Hydroxybupropion did not elicit a response in 5-HT 3A or 5-HT 3AB expressing oocytes when applied alone ( Fig 3C) .
Effect of Pre-incubation with Bupropion and Hydroxybupropion on 5-HT 3A and 5-
HT 3AB Receptors
Bupropion's allosteric inhibition of 5-HT 3A R is not dependent on the opening of the receptor's channel; it is non-use dependent (Pandhare, 2017) . To evaluate the extent of inhibition evoked by pre-incubating oocytes expressing 5-HT 3A and 5-HT 3AB R with bupropion or its metabolite, results were compared to the current amplitudes resulting from co-application of 5-HT and bupropion/hydroxybupropion. First, oocytes were perfused with 5-HT (~EC 30 , 5-HT 3A R: 0.5 μ M, 5-HT 3AB R: 2 μ M) and bupropion (~IC 50 , 5-HT 3A R: 100 μ M, 5-HT 3AB R: 1 mM) to obtain the control current ( Fig. 4A ). Once a stable response was achieved, a constant IC 50 concentration of bupropion was exposed to the receptors for exactly 5 min before another co-application of the same 5-HT and bupropion solutions. Pre-incubation decreased the current amplitude of 5-HT 3A R to 76.1±3.20% (Fig. 4C , left panel) of control, consistent with previous findings (Pandhare, 2017) . On the contrary, under the same experimental conditions, 5-HT 3AB R was greatly affected by pre-incubation, which resulted in a current amplitude reduced to 35.5±2.29% of the control current ( Fig. 4C , right panel). Similar results were obtained from hydroxybupropion pre-incubation ( Fig. 4B ). Compared to co-application alone, preapplication resulted in a greater depression of current for 5-HT 3A R and 5-HT 3AB R with hydroxybupropion ( Fig. 4C , 5-HT 3A R: 93.0±2.50% and 5-HT 3AB R: 46.1±2.47% of control current).
Recovery times for Bupropion inhibition
Bupropion's antagonistic effect on 5-HT-evoked inward currents has been shown to be reversible (Pandhare, 2017) . To evaluate the recovery times for 5-HT 3A R and 5-HT 3AB R, bupropion at an IC 200 concentration was applied for 60 s to show an observable effect on the oocyte's current amplitudes and to better measure the time required to reverse the inhibitory effect. For these experiments, the ~EC 50 concentration of 5-HT (grey bars, 5-HT 3A R: 0.8 μ M, 5-HT 3AB R: 5.0 μ M) was applied episodically after washing in between each application (5-HT 3A R: 2 min, 5-HT 3AB R: 90 s minimum). These agonist-induced currents led to minimal run-down and the difference in current amplitudes was less than 5% ( Fig. 5A ). Sample traces of current recovery following bupropion application and removal are shown in Fig. 5B (left: black, 5-HT 3A R, right: green, 5-HT 3AB R). The first current response is the control current evoked by the agonist alone. Once a stable current response was obtained, bupropion was applied without the agonist for 60 s (magenta bars, ~IC 200 , 5-HT 3A R: 400 μ M; 5-HT 3AB R: 4 mM). Subsequently, the agonist was either applied immediately or after 10, 30, or 60 s ( showed a larger decrease in current amplitude after bupropion application and immediate 5-HT perfusion, not only with regard to the current amplitude but also its effect on the characteristically fast desensitization kinetics. Direct application of 5-HT after 60 s exposure to 4 mM bupropion led to a slow inward current that showed no desensitization but a slowly increasing current that never stabilized and was terminated after ~3 min ( Fig. 5B , first trace, right panel). After further washing, the fast activating inward current response exhibiting desensitization could be recovered. Due to the lack of a stable current response after 0 s of washing, the lowest current amplitude recorded was after 10 s of wash for 5-HT 3AB R, with 18.1±2.19% of the initial current response ( Fig   5C, right panel) . Rapid recovery of current amplitude was achieved by increasing the wash times between bupropion and 5-HT applications ( Fig 5C, right panel) . 5-HT 3A R
and 5-HT 3AB R both show stepwise and time-dependent recovery from bupropion inhibition, and can be fully reversed after 7+ min wash time.
Voltage-independent binding of Bupropion
To determine if bupropion binds to 5-HT 3 R in a voltage-dependent manner, 5-HTinduced currents (~EC 50 ; 5-HT 3A R: 0.8 µM; 5-HT 3AB R: 5.0 µM) were evoked in oocytes expressing 5-HT 3A R and 5-HT 3AB R at two different holding potentials, +40 and -40 mV ( Fig 6A) . First, the control current was obtained at positive and negative voltages before the co-application of 5-HT and bupropion (~IC 50 ; 5-HT 3A R: 100 µM; 5-HT 3AB R: 1mM).
Bupropion reduced the current amplitudes of homo-and heteromeric receptors at both voltages. The mean fractional block was recorded at each voltage and normalized to the control current ( Fig 6B; 5-HT 3A R: 55.8±0.06%, 59.8±0.05%; 5-HT 3AB R: 56.6±0.02%, 59±0.04%; -40 and +40 mV respectively, n=4). For 5-HT 3A R and 5-HT 3AB R, this fractional inhibition is similar at positive and negative voltages (paired t-test, 3A:
t(3)=1.106, p=0.349; 3AB: t(3)=0.291, p=0.790). Based on these results, inhibition of 5-HT-induced currents by buproprion is independent of voltage.
Bupropion at physiological concentrations and its effect on 5-HT 3A R and 5-HT 3AB R
To better understand the clinical significance of the bupropion-induced inhibition of 5-HT 3 R, 5-HT-induced currents were measured in the presence of a clinically relevant bupropion concentration (~20 µM, (Schroeder, 1983; Vazquez-Gomez, 2014) ). First, oocytes expressing 5-HT 3A R and 5-HT 3AB R were exposed to three different 5-HT concentrations (0.5, 1.0, 5.0 µM) in the absence of bupropion to obtain the initial current amplitudes ( Fig 7A, black, left panel: 5-HT 3A R, green, right panel: 5-HT 3AB R). Next, the oocytes were continuously perfused with 20 µM bupropion and the same 5-HT concentrations were re-applied; the oocytes were pre-incubated with bupropion for at least for 2 minutes prior to 5-HT application ( (n=4), whereas 5-HT 3AB R showed a ~23% decrease in current (n=5, Fig 7B) .
Discussion
Our results, for the first time, demonstrate that bupropion antagonizes heteromeric 5-HT 3AB receptors and that the kinetics of inhibition are distinct from 5-HT 3A R. Twoelectrode voltage clamp experiments indicate that bupropion reversibly inhibits 5-HTinduced currents of Xenopus oocytes expressing 5-HT 3A and 5-HT 3AB R in a concentration-dependent manner, with inhibitory potencies of 87.1 μ M (same as previously reported (Pandhare, 2017)) and 866 μ M respectively. Similar to other noncompetitive antagonists (such as picrotoxin (Das, 2003) ), bupropion has a lower potency (~10-fold) at 5-HT 3AB R compared to 5-HT 3A receptors and, therefore, could be used to discriminate between these two receptors (Thompson, 2013) .
In humans, bupropion is extensively metabolized to the active metabolites hydroxybupropion and threohydrobupropion (Schroeder, 1983) . One of these major metabolites, hydroxybupropion, is known to contribute to the biological efficacy of the parent drug (Bondarev, 2003; Damaj, 2004; Martin, 1990) . Similarly to bupropion, the metabolite inhibits nAChR and 5-HT 3A R in a non-competitive manner (Damaj, 2004; Pandhare, 2017) and also shares a comparable potency (unpaired t-test, p value=0.08464) for the homomeric receptor (5-HT 3A R: IC 50 = 113 μ M, similar to previously reported data (Pandhare, 2017)). In contrast, hydroxybupropion exhibits a ~4.5-fold shift in IC 50 (5-HT 3AB R: IC 50 = 505 μ M).
Interestingly, bupropion and hydroxybupropion potentiate 5-HT-induced currents of 5-HT 3AB R at low concentrations when co-applied with the agonist (Bup: 30 μ M:
122.6±8.0%, n = 6; HydroB: 50 μ M: 109.9±4.31%, n = 5), a phenomenon not observed with the 5-HT 3A R. Similar potentiation has been observed for the antagonist atropine at neuronal nicotinic acetylcholine receptors (Parker, 2003; Zwart, 1997) . Atropine potentiates acetylcholine-induced inward currents at low concentrations of the agonist but shows antagonistic activity at high concentrations of agonist or atropine. This phenomenon may be due to the drug acting on two distinct sites: one non-competitive inhibitory site and a second site associated with competitive potentiation (Zwart, 1997).
Since we only observed potentiation in heteromeric 5-HT 3AB channels, this may indicate that the 3B subunits are mediating this effect. The 3B subunits potentially contribute directly to the potentiating binding site or mediate the effect via an allosteric mechanism.
Bupropion-mediated inhibition of 5-HT 3A R is non-use dependent (Pandhare 2017); the drug can access its binding site in a closed receptor state and inhibit the transition to an open state. In general, use-dependent block, or inhibition that would require a channel to be open to occur, is not influenced by pre-application. We evaluated the effect of a 5min pre-incubation with bupropion and its metabolite hydroxybupropion on the homomeric and the heteromeric receptor ( Fig. 4 ). Pre-incubation with inhibitor lead to an increased inhibition in all cases when compared to co-application, indicating that the block is non-use dependent for both receptors. Our observation that bupropion's inhibition of 5-HT 3 R is voltage-independent additionally concurs with it not acting as an open channel blocker (Choi, 2003; Garcia-Colunga, 2011; Gumilar, 2003; Gumilar, 2008; Slemmer, 2000) . Similar results are shown with other antidepressants at 5-HT 3 R (Eisensamer, 2003) and with bupropion at nAChR (e.g. α
for an external binding site for bupropion (Garcia-Colunga, 2011; Slemmer, 2000) .
Considering different binding sites within the family of AChR (Pandhare, 2012), bupropion may have distinct binding sites in each channel (Arias, 2009b) .
We saw a greater depression of current amplitudes when bupropion or its metabolite was pre-incubated as compared to co-application with 5-HT ( blocks the receptor prior to the opening of the channel, therefore presumably interacting with the closed channel and potentially inhibiting the channel from opening (Arias, 2009b; Choi, 2003) . Consistent with other data, greater potencies of inhibition have been reported for bupropion and tricyclic antidepressants on Cys-loop receptors in the resting state than the open state (Arias, 2009b; Choi, 2003; Gumilar, 2008) . This phenomenon may be due to the accumulation of antidepressants and antipsychotics in the cell membrane during pre-incubation, which may be important for the functional antagonistic effects of these drugs at the 5-HT 3 receptor (Eisensamer, 2005).
Bupropion's inhibition of 5-HT-mediated currents is reversible after a substantial amount of washing. In this study, we investigated the time it takes for 5-HT 3 R to recover from pre-incubation with bupropion at high concentrations (~IC 200 ; 5-HT 3A R: 400 µM; 5-HT 3AB R: 4 mM). Similarly to our pre-incubation experiments, bupropion reduced 5-HT 3A R currents significantly but to a lesser extent than 5-HT 3AB R. The largest reduction of current was observed with the shortest amount of wash time between the bupropion and agonist applications (5-HT 3A R: 82.4±1.78% after 0 s wash; 5-HT 3AB R: 18.1±2.19%
of the control current after 10 s wash). For 5-HT 3AB R, the immediate switch to 5-HT could not be quantified because the current never stabilized and was continuously increasing. This behavior is very uncharacteristic for 5-HT 3AB R. We speculate that this high concentration of bupropion may accumulate in the membrane and stabilize the receptor in a closed position. In the 5-HT 3AB R trace we may be observing the effect of bupropion being washed away over time during the application of the agonist, which results in the receptor opening and a very prolonged inward current. 5-HT 3A and 5-HT 3AB receptors show a time-dependent recovery from bupropion's inhibition, and their currents could be fully recovered after ~7.5 min of washing.
The clinical relevance of 5-HT 3 -inhibition by bupropion is currently unknown. Bupropion, but not its metabolites, concentrates in many tissues, with a brain to plasma ratio of 25:1 (Schroeder, 1983) , which results in brain concentrations of ~20 µM (Vazquez-Gomez, 2014) . Although 20 μ M bupropion co-applied with agonist minimally inhibits 5-HT-induced currents of 5-HT 3A R and possibly potentiates HT 3AB R, pre-incubation with bupropion has a significant impact on its inhibitory effect ( Fig. 7) . Our results indicate that 5-HT 3 receptors are significantly inhibited by 20 µM bupropion with a minimal pre-incubation time of 5 minutes (5-HT 3A R: ~82.7% 5-HT 3AB R: ~74.9% of control current).
Moreover, hydroxybupropion also contributes to bupropion's antidepressant activity (Bondarev, 2003; Damaj, 2004; Martin, 1990) . The metabolite reaches ~10-fold higher plasma concentrations in humans as compared to the parent drug (Findlay, 1981; Golden, 1988; Hsyu, 1997) : with an average of almost 100 µM (based on clinical data, test ID: FBUMT; Mayo Clinic, MN), hydroxybupropion's plasma concentrations are equivalent to 5-HT 3A R's IC 50 value. Additionally, considering the increased inhibitory effect due to pre-incubation of 5-HT 3 R, we conclude that bupropion and hydroxybupropion have the potential to inhibit these receptors at physiologically relevant concentrations.
The comprehensive mechanism by which bupropion achieves its therapeutic efficacy is multifactorial. Bupropion inhibits nAChR and reuptake transporters for dopamine and (Bétry, 2011) , and are found both pre-and post-synaptically where they modulate the release of many other neurotransmitters (Chameau, 2006; Faerber, 2007; Miquel, 2002; Nayak, 2000) . For instance, 5-HT 3 receptors and GABAergic neurons show strong interactions in the hippocampus and neocortical cells (Morales, 1996; Morales, 1997) . Additionally, 5-HT 3 receptors mediate stress-dependent activation of dopaminergic neurotransmission (Bhatt, 2013; Devadoss, 2010) . Although 5-HT 3 antagonist's clinical relevance is mainly concerned with emesis, several studies have reported their potential role for treating mood and anxiety disorders (Bhatt, 2013; Thompson, 2007; Walstab, 2010) . In humans, 5-HT 3 antagonists show improvements of comorbid depression for patients suffering from complex disorders (Faris, 2006; Haus, 2000) . Animal studies conclude that the antagonist's anxiolytic activity is due to the inhibition of limbic hyperactivity responses (Bhatt, 2013) , supported by the results that 5-HT 3A R gene deletion produces an anxiolytic phenotype in mice (Kelley, 2003a) . Furthermore, 5-HT 3 antagonists have implications on hippocampal long-term potentiation (Bétry, 2011), increase synaptic NE levels, and facilitate 5-HT neurotransmission of other 5-HT receptors (Rajkumar, 2010).
Also, several clinically available antidepressant and antipsychotic drugs have antagonistic activities at 5-HT 3 receptors (Bétry, 2011; Choi, 2003; Eisensamer, 2003; Rammes, 2004) . Interestingly, 5-HT 3 antagonists have shown to enhance the antidepressant action of bupropion (Devadoss, 2010). In conclusion, 5-HT 3 and nACh receptors have shown many implications in the neurobiology of depression and a highly complex interplay can be expected between these systems. Currently, it is not known if bupropion-or hydroxybupropion-mediated inhibition of 5-HT 3 receptors is clinically relevant for their antidepressant activity. We show here that bupropion inhibits 5-HT 3 receptors at clinically-relevant concentrations, and that this inhibition may contribute to bupropion's desired and undesired clinical effects. . 5-HT 3AB R bottom panel, bar graph showing that a low concentration of 50 µM hydroxybupropion in the presence of 2 µM 5-HT elicits potentiation (109.9±4.31%, n = 5) in 5-HT 3AB R (B) Currents were normalized to the control currents and yielded the following IC 50 values, 5-HT 3A R: IC 50 = 113 µM (n H = 1.17±0.06, n = 5, means ± S.E.M.), 5-HT 3AB R: IC 50 = 505 µM (n H = 1.57±0.12, n = 8, means ± S.E.M.) (C) Oocytes expressing 5-HT 3A R and 5-HT 3AB R did not elicit an inward current in response to hydroxybupropion alone. 
